Table 1.

Patient Baseline Characteristics

Characteristic	All Patients (N = 174)	Patients With Imatinib-Resistant Disease (n = 161)	Imatinib-Intolerant Patients (n = 13)
Age, years
Median	57	56	61
Range	22-86	22-86	29-80
Male, %	55	57	31
Duration of CML at study entry, months
Median	82	82	91
Range	4-359	4-359	4-206
Extramedullary involvement, %	23	22	31
Splenomegaly	21	21	31
Outside spleen	6	6	8
BCR-ABL mutation*
No. of patients	88	87	1
Total patients analyzed	156	145	11
%	56	60	9
Prior therapy, %
Interferon-α	72	73	62
Stem-cell transplantation	13	13	15
Chemotherapy	59	60	46
Hydroxyurea or anagrelide	94	94	92
Radiotherapy	4	4	8
Imatinib therapy duration, %
< 1 year	10	7	46
1-3 years	31	30	39
> 3 years	59	63	15
Highest imatinib dose, %
400-600 mg	48	45	77
> 600 mg	52	55	23

Abbreviation: CML, chronic myelogenous leukemia.

^*Percentage based on number of patients with baseline mutation analysis available.